European Federation of Neurological Societies/Peripheral Nerve Society Guideline * on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society
European Federation of Neurological Societies/Peripheral Nerve Society Guideline * on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society
复制标题
欧洲神经学会联合会/周围神经学会指南*关于慢性炎症性脱髓鞘性多发性神经根神经病的治疗。
DOI：
10.1111/j.1085-9489.2005.10302.x
复制
发表时间：
2005
影响因子：
3.8
通讯作者：
I. N. Schaik
中科院分区：
文献类型：
--
作者：
R. Hughes;P. Bouche;D. Cornblath;E. Evers;R. Hadden;A. Hahn;I. Illa;C. Koski;J. Léger;E. Nobile‐Orazio;J. Pollard;C. Sommer;P. Bergh;P. Doorn;I. N. Schaik
摘要背景 ：许多套诊断标准已试图定义慢性炎性脱髓鞘性多神经根神经病（CIDP），随机试验和治疗的系统评价已经发表。目的：本指南的目的是制定关于CIDP定义、调查和治疗的共识指南。研究方法：疾病专家和患者代表考虑了2004年5月从MEDLINE和科克伦系统评价中检索到的参考文献，并准备了以迭代方式达成一致的声明。建议：工作组商定了良好做法要点，以确定CIDP的临床和电生理诊断标准，包括或不包括要考虑的伴随疾病和检查。主要治疗建议如下：（1）感觉和运动CIDP应考虑静脉注射免疫球蛋白（IVIg）或皮质类固醇（B级推荐）;（2）IVIg应被视为纯运动性CIDP的初始治疗（良好实践点）;（3）如果IVIg和皮质类固醇无效，应考虑血浆置换（A级建议）;（4）如果反应不足或初始治疗的维持剂量较高，应考虑联合治疗或添加免疫抑制剂或免疫调节药物（良好实践点）;（5）应考虑对症治疗和多学科管理（良好实践点）。
Abstract Background: Numerous sets of diagnostic criteria have sought to define chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and randomized trials and systematic reviews of treatment have been published. Objectives: The aim of this guideline was to prepare consensus guidelines on the definition, investigation, and treatment of CIDP. Methods: Disease experts and a representative of patients considered references retrieved from MEDLINE and Cochrane Systematic Reviews in May 2004 and prepared statements that were agreed in an iterative fashion. Recommendations: The Task Force agreed on good practice points to define clinical and electrophysiological diagnostic criteria for CIDP with or without concomitant diseases and investigations to be considered. The principal treatment recommendations were as follows: (1) intravenous immunoglobulin (IVIg) or corticosteroids should be considered in sensory and motor CIDP (level B recommendation); (2) IVIg should be considered as the initial treatment in pure motor CIDP (good practice point); (3) if IVIg and corticosteroids are ineffective, plasma exchange should be considered (level A recommendation); (4) if the response is inadequate or the maintenance doses of the initial treatment are high, combination treatments or adding an immunosuppressant or immunomodulatory drug should be considered (good practice point); and (5) symptomatic treatment and multidisciplinary management should be considered (good practice point).